Latest TYSABRI Stories
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that a post-hoc analysis showed TYSABRI(R) (natalizumab) treatment increases the probability of achieving sustained improvement in physical disability over two years when compared to placebo.
Biogen Idec (NASDAQ: BIIB) will present new data on the company's leading multiple sclerosis (MS) franchise at the World Congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal, Canada.
Elan and Biogen Idec have initiated the first clinical trial of Tysabri in oncology. The first dose of Tysabri was administered earlier in the trial.
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) today announced the initiation of the first clinical trial of TYSABRI(R) (natalizumab) in oncology. The first dose of TYSABRI was administered yesterday in the trial.
SCOTTSDALE, Ariz., Aug. 20 /PRNewswire/ -- MedPredict, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for multiple sclerosis (MS) therapies.
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the two-year anniversary of TYSABRI(R) (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS), marking the reintroduction of the product in the United States (US) and the first international approval.
The Food and Drug Administration (FDA) announced Monday it had approved Tysabri, a drug used to treat multiple sclerosis, for use in patients with moderate to severe Crohnâ€™s disease.
U.S. health officials cleared the way on Monday for multiple sclerosis drug Tysabri to return to the market with restrictions, following its withdrawal last year when it was linked to a rare but potentially fatal brain disease.
WASHINGTON (Reuters) - Biogen Idec Inc. and Elan Corp. won permission on Monday to resume sales of their multiple sclerosis drug Tysabri, which was withdrawn last year after it was linked to a rare but potentially fatal brain disease, U.S. regulators said. The U.S.
- To swell, as grain or wood with water.